US STOCKS-Futures retreat; main indexes on track for weekly gains

(For a Reuters live blog on U.S., UK and European stock
markets, click LIVE/ or type LIVE/ in a news window.)
* Futures down: Dow 0.53%, S&P 0.65%, Nasdaq 0.83%

By Shivani Kumaresan
April 30 (Reuters) - U.S. stock index futures retreated on
Friday as investors hit pause after a barrage of strong earnings
and upbeat economic data through the week drove the benchmark
S&P 500 index to record levels.
A rally in shares of big technology companies following
their impressive results has put all three major indexes on
track for weekly gains, while setting up the Nasdaq index
.IXIC for a sixth straight month of increase.
The S&P 500 .SPX and Dow Jones Industrial Average .DJI
are also on course for their third straight monthly gains.
Amazon.com Inc AMZN.O rose 2.3% in premarket trading after
posting record profits and signaling that consumers would keep
spending in a growing U.S. economy and converts to online
shopping are not likely to leave. Twitter Inc TWTR.K plunged 12.7% as it offered tepid
revenue forecast for the second quarter, saying user growth
could slow as the boost seen during the coronavirus pandemic
fizzles.
Other high-flying stocks, including Facebook Inc FB.O ,
Alphabet Inc GOOGL.O , Apple Inc AAPL.O and Netflix Inc
NFLX.O , fell between 0.9% and 1.8%.
Data on Friday is expected to show U.S. consumer spending
likely jumped 4.1% in March after slipping 1% in February, with
the core PCE index, the Federal Reserve's preferred inflation
measure, also expected to rise last month.
At 6:52 a.m. ET, Dow e-minis 1YMcv1 were down 180 points,
or 0.53%, S&P 500 e-minis EScv1 were down 27.25 points, or
0.65%, and Nasdaq 100 e-minis NQcv1 were down 116 points, or
0.83%.
Chevron Corp CVX.N shed 2.0% after its first-quarter
profit fell 29%, hit by weaker refining margins and production
losses. Gilead Sciences Inc GILD.O fell 2.8% after its
first-quarter revenue fell short of Wall Street estimates as the
coronavirus pandemic hurt sales of its flagship HIV and
hepatitis C drugs.